Mimedx Group reports $62.28M revenue

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

What changed since last quarter

1 new risk factor · 4 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

New risk factors (1)

An investment in our Common Stock involves a substantial risk of loss. You should carefully consider the risks described below, together with the other information contained in this Quarterly Report on Form 10-Q and the risk factors previously disclosed in Part I, Item 1A, Risk Factors, of our Annual Report on Form… +15 more paragraphs

New legal mentions (4)

Consummation of the Acquisition remains subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ( HSR ), and the satisfaction of other customary closing conditions.
The Company received a Warning Letter from the FDA on December 21, 2023, relating to the inspections and classification of AXIOFILL. +1 more paragraph
In September 2026, the Court issued an order vacating the FDA's determinations that AXIOFILL is not a Section 361 HCT/P because it is more than minimally manipulated and that AXIOFILL should be classified as a biological product rather than a medical device, and remanded both matters to the FDA for further… +2 more paragraphs
For a description of material legal and regulatory proceedings, including the Company s litigation challenging the FDA s regulatory classification of AXIOFILL, see Note 12, Commitments and Contingencies Litigation and Regulatory Matters , to the unaudited condensed consolidated financial statements included in Part…

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.